Evelo Biosciences, Inc. is discovering and developing therapies designed to engage immune cells in the small intestine to drive therapeutic immune effects throughout the body for the treatment of inflammatory diseases and cancers. The action of its therapies is based upon the observation that immune cells in the small intestine have a central role in governing the immune, metabolic and neurological systems throughout the body. The Company’s monoclonal microbials are orally-delivered pharmaceutical compositions of naturally-occurring, specific single strains of microbes. Evelo currently has five product candidates: EDP1815, EDP1867, EDP2939 and EDP1632 for the treatment of inflammatory diseases, and EDP1503 for the treatment of cancer.